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BACKGROUND 
 Chemsex has been defined as engaging in sexual activities while under the influence of 
specific recreational drugs (Crystal Methamphetamine, Mephedrone and γ-hydroxybutyrate 
(GHB) 1) taken before or during sex. This typically occurs between men who have sex with 
men (MSM) and is associated with high-risk sexual practices (group sex and condomless 
anal intercourse
2,3
) which in turn may result in increased transmission of sexually transmitted 
infections (STI’s), enteric infections (notably Shigellosis3), Hepatitis C and HIV4 
Multiple studies have demonstrated that MSM are more likely to have used recreational drugs 
then men who have sex exclusively with women2, 5,6.  In The Astra Study2 half of the HIV-
positive MSM studied reported recreational drug use in the previous 3 months: Among these 
nearly 20% reported condomless sex with partners of unknown HIV status and 32% group 
sex.  
Targeted chemsex services have been developed in some Sexual Health Clinics (SHCs). 
‘The Chemsex Study’7 demonstrated, via qualitative interviews that in general, MSM felt 
comfortable discussing chemsex within Sexual Health Clinics (SHCs). 
There are limited data available from the United Kingdom (UK) on the prevalence and 
frequency of chemsex in MSM and most are from SHCs in London or other large 
conurbations reflecting larger MSM populations in these areas.  We undertook a survey of 
SHC healthcare workers  (HCWs) to explore demand for and availability of chemsex services 
across the UK including in less urban areas, to inform service planning. 
METHOD  
Survey development and implementation 
An online survey including questions on frequency of ‘chemsex consultations’ (patient 
reporting chemsex to medical staff during consultation), staff training, specialist services and 
clinic policies was developed using ‘Select Survey’8 software with input from collaborating 
HCWs with clinical interest in chemsex. The survey was piloted by 2 SHC’s and the members 
of British Association for Sexual Health and HIV (BASHH) National Audit Group (NAG) with 
no significant changes. (Appendix 1) The survey included two parts: Part 1 covered clinic 
policy and 2 clinical experiences and training. As a service development project a review by 
the research ethics committee was not required.   
The survey was distributed to all level 39 UK SHCs (complex service provision) via an email to 
clinical staff facilitated by trainee and NAG representatives. Non-responding clinics were sent 
reminders at one week.  
Recipients were asked to distribute the survey to clinical staff including the most junior team 
members screening patients for STIs.  To limit bias due to those with an interest in chemsex 
responding disproportionately only staff that worked on a specific day were invited to 
participate (except clinical leads who were asked to complete the survey regardless). 
Clinical leads were asked to complete part 1.  All respondents were asked to complete part 2. 
Data analysis 
Results were analysed by clinic. Where there were multiple responses per clinic, one 
response was selected for analysis, as follows:  
(a) Any clinic with at least one respondent reporting chemsex consultations. 
(b) Among the chemsex consultation clinics, the following hierarchy was applied, based on 
decreasing size of the respondent group: (i) nurses, (ii) doctors, (iii) HA’s and (iv) ‘other’. The 
exception was for the analysis of part 1 which was directed only at clinical leads.  
 
For clinics in England, data were available from the national STI surveillance system 
(GUMCAD) 10 and were used, along with data from the Office for National Statistics Rural-
Urban Classification for Local Authority Districts in England 11, to stratify clinics into four geo-
demographic categories:  (A) Urban conurbation, (B) urban with city/town, (C) urban with 
significant rural and (D) non- urban. Similar data were not available for non-English clinics 
which were therefore not stratified in the same way. 
  
For clinic based analysis, Fisher’s exact test with Bonferroni correction was used to examine 
associations between responses given by HCWs and regional variations (i.e. rural/urban) of 
the participating clinics. STATA v.13.1 was used for analysis and p values less than 0.01 
were considered statistically significant (chosen after Bonferroni correction to address the fact 
that the probability of obtaining a spurious result increases with more tests taken).  
Not all respondents answered each question leading to small variations in the denominators.  
RESULTS 
UK, RESPONDENT BASED DATA (results from all respondents) 
Survey responses were received from 348 individuals from 56% (150/270) of UK SHCs. The 
majority were from English clinics (90%, 313/348). 1% (3/348) were from Scottish, 1% (4/348) 
Northern Irish (NI) and 3% (10/348) Welsh clinics. This represents an overall clinic response 
rate of; 63 %( 135/214) for England, 8 %( 3/39) Scotland, 80% (4/5) NI and 83% for (10/12) 
Wales. For England, clinic contact details were available via GUMCAD. Similar information 
was not available outside of England and this may be reflected in lower response rates. 
Using data about currently open English SHC’s, the response rates by geo-demographic 
regions can be estimated as; 51%(40/78) for groups A, 53% (41/68) B, 59%(16/27) C and 
47% (16/34) for D.  
Most respondents worked in the following roles; Nurses (41% 144/348), Doctors (24% 84/348 
consultants, junior doctors (5% 16/348), associate specialists (7% 24/348), and HA’s (15%, 
52/348). There were a small number of respondents who worked in ‘other’ roles. 
 CLINIC POLICY (Clinical leads only) 
With regards to clinic policy, data from 20 % (55/270) of consultant clinical leads were 
available for analysis (1 clinical lead response per clinic selected). (48 England, 1 Scotland, 4 
Wales, 2 N.I). For the majority of policy questions there were 44 responses. (44/55, 80%). 
Due to the lower numbers, a geo-demographic analysis was not performed.  
11% (5/44) reported that a history of chemsex was routinely asked of all patients, 68% 
(30/44) selected patients and the remainder that it was not routinely asked.  
Asked whether clinic policy requires documentation of a chemsex history in new patients, 
69% (33/48) reported that it was not, 19 %( 9/48) that it was for selected patients and 13% 
(6/48) for all patients. Where chemsex was reported, the documentation of associated harms 
(acute or chronic- physical, psychological, social or financial) was clinic policy in 10.4% (5/48) 
of clinics.  
Where referral for ongoing management was required, 54% (23/43) reported patient self-
referral, 33% (14/43) a formal referral process, and 14% (6/43) informal referral processes. 
With regards to referral follow-up, 83% (39/47) did not have a process in place, 13% (6/47) 
did and 4% (2/47) did not know.  
CLINC-BASED ANALYSIS 
Demand for chemsex services  (Table 1) 
80% (103/129) of clinics reported ever seeing patients reporting chemsex and 50% (65/129) 
that such consultations occurred at least monthly. These figures did not vary greatly across 
the UK (Fishers, p=0.64).  
A demand for a local chemsex service was reported by 67% (87/129) of clinics.   
Chemsex Interventions (select all that apply)  
The most commonly reported interventions used were simple advice (90%, 43/47), sign-post 
to NHS substance misuse services (53%, 25/47), external needle exchanges (55%, 26/47), 
brief-behavioural interventions (53%, 25/47) and sign-post to online resources (49%, 23/47). 
In-house chemsex and needle exchange interventions were available to 11% (5/47) of clinics, 
3 of which were in London.  
Training  
38% (44/114) of all respondents reported receiving chemsex training. This did not vary 
significantly by geo-demographic category in England, (Fishers, p = 0.016, table 1) 
Respondents from all but one clinic (99%, 117/118) reported that there was a need for 
chemsex training but only 38% (44/117) reported previously having received training (Table 
1). The most frequent areas of training requested were: Withdrawal (81%, 96/118), 
terminology (80%, 94/118), long-term harms of drug use (75%, 89/118), drug interactions 
(75%, 88/118, 75%), acute harms (69%, 82/118), assessment of ‘problematic’ chemsex(66%, 
78/118) and history-taking (63%, 74/118). 
Geo-demographic Analysis (England only, Table 1) 
In England, responding clinics were categorised in the following geodemographic regions: A - 
urban conurbation (35%, 40/113), B - urban with city/town (36%, 41/113), C- urban with 
significant rural (14%, 16/113), and D - non-urban (14%, 16/113).  
There was no significant difference in those reporting chemsex consultations or of the 
frequency of such consultations by geo-demographic region (p=0.38; Table 1). Similarly there 
was no significant difference in training requirement (p=0.016).  
Response rates by geo-demographic region, to the question surrounding chemsex 
consultation frequency were 88-90% for groups A, B and D and 69% for group C. 
DISCUSSION 
Our study suggests that patients reporting chemsex regularly present to SHCs throughout the 
UK, even in rural areas, and that while some have well-defined policies and care pathways in 
place, this is far from universal. Most clinics took a patient-targeted approach in establishing a 
chemsex history, lacked local chemsex specific services and had largely informal referral 
processes with no follow-up. The lack of a consistent approach across SHC’s in England, 
Wales and Scotland is concerning, and clinical management of patients might be improved in 
some settings.  
Our national, clinic-based survey provides much needed information about HCWs 
experiences of the demand for and availability of chemsex services, and the need for training 
about chemsex. More than half of all level three SHCs responded, such that we can be 
reasonably confident in generalising the findings in England and Wales, but caution is 
required when generalising to Scotland where response rates were lower.  
There are important limitations of this work. Incomplete responses to some questions will 
have introduced inaccuracies. We cannot exclude the possibility that respondents were more 
likely to be HCWs with a particular interest in chemsex, resulting in over-estimation of the 
frequency of chemsex-related consultations. This was a self-reported survey and the results 
represent the views of the individuals responding and may not therefore accurately represent 
the whole clinic experience. Variability in respondents’ roles will have influenced their 
knowledge and experience of, and expertise in, chemsex consultations in their clinic.  
Appropriately targeted chemsex services may help to limit risk-taking behaviours and 
associated infections. One large London service demonstrated lower hepatitis C co-infection 
rates (25%) within 2 years of implementing a chemsex service compared to other London 
clinics without such services (40%). 12 Addressing chemsex may have wider, positive impacts 
on patients’ mental, social, financial and general health, as evidenced by a retrospective case 
review in one London service that revealed that half of MSM reporting chemsex perceived 
subsequent adverse consequences on their physical and mental health or career13.  
The lack of chemsex specific services reported here may not be unreasonable given the 
variation in resources and service demand but an established clinical pathway for patient 
management should be available to all. The development of clinical networks (such as a hub 
and spoke model where the “hub” is the specialty’s primary site and the “spokes” are 
connecting secondary sites serving that specialty) coupled with robust referral pathways 
might help to ensure that all patients have access to appropriate services regardless of their 
location. Such services should be non-judgmental, LGBT-friendly and able to assess and 
address the potential physical, psychological, social and financial harms associated with 
chemsex. Physical harms may include (amongst others) STI’s or blood-borne viral infections, 
injecting site infections and withdrawal14.  
Where chemsex is identified, clinicians need to be competent in assessing if this is 
problematic and in arranging appropriate intervention or referral. The development of a short 
screening tool could facilitate this. Universally accessible, up-to-date chemsex training is 
required, as evidenced by the 99% of respondents requesting further training. Two of the 
most requested training areas were about managing withdrawal and long-term harms related 
to drug use, issues traditionally managed in drugs and alcohol services. Collaboration, 
integration and possible co-location with such services for clinical delivery of chemsex 
services and training could be mutually beneficial. Further investigation is required to obtain a 
clearer picture of chemsex in the UK and a comprehensive survey involving patients directly 
is planned by PHE to help improve and direct services. Similar work in traditional drug and 
alcohol settings would also be beneficial. Routine questioning of all patients about chemsex 
would help to clarify the frequency of chemsex consultations in the UK and therefore guide 
service design and delivery. In England, PHE intend to introduce chemsex monitoring through 
routine national surveillance, and preliminary findings are promising11, 15.  
Our study suggests that the issue of chemsex is relevant to most SHC’s across the country. It 
is critical that all patients participating in chemsex have access to local high quality, 
appropriate services to improve their health and well-being and avoid future harms. Improving 
training, developing clear care-pathways and collaboration between sexual health clinics 
could help deliver safe and effective treatment for this high-risk group of patients 
.  
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